New obesity drug combo shows promise in early trial

NCT ID NCT04969939

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding an experimental drug (NNC0165-1875) to the weight-loss medication semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the drug combo or semaglutide plus a placebo, with two injections per week. The study lasted about 26 weeks and looked at safety and weight change.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NNC0165-1875 (an experimental drug) added to semaglutide

What this could lead to

If it works, this could lead to a more effective weight-loss treatment for people with obesity.

What could go wrong

This is a small, early-phase trial (phase 2) with only 120 participants. The drug combination may not prove safe or effective in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

AMC Community Endocrinology

Albany, New York, 12206, United States
Accellacare

Wilmington, North Carolina, 28401, United States
Altasciences Clinical Kansas, Inc.

Overland Park, Kansas, 66212, United States
Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States
Chrysalis Clinical Research

St. George, Utah, 84790, United States
Coastal Carolina Res Ctr.

North Charleston, South Carolina, 29405, United States
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
East West Med Res Inst

Honolulu, Hawaii, 96814, United States
Endo Res Solutions Inc

Roswell, Georgia, 30076, United States
Evanston Premier Hlthcr Res

Skokie, Illinois, 60077, United States
Health Res of Hampton Roads

Newport News, Virginia, 23606, United States
Jacksonville Ctr For Clin Res

Jacksonville, Florida, 32216, United States
L-MARC Research Center

Louisville, Kentucky, 40213, United States
Medical Uni of SC Charleston

Charleston, South Carolina, 29425, United States
NYC Research, Inc.

New York, New York, 10016, United States
National Clin Res Inc.

Richmond, Virginia, 23294, United States
PharmQuest Life Sciences LLC

Greensboro, North Carolina, 27408, United States
Profil Institute For Clinical Research Inc

Chula Vista, California, 91911, United States
Selma Medical Associates

Winchester, Virginia, 22601-3834, United States
Soltero Cardiovascular Research Center

Dallas, Texas, 75226, United States
Texas Diabetes & Endocrinology, P.A._Austin

Austin, Texas, 78749, United States
Texas Diabetes & Endocrinology, P.A._Austin

Round Rock, Texas, 78681, United States
Univ of Alabama Birmingham

Birmingham, Alabama, 35294, United States
Velocity Clin Res Los Angeles

Los Angeles, California, 90017, United States
Washington Cntr Weight Mgmt

Arlington, Virginia, 22206, United States